- Original investigation
- Open Access
Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort
Cardiovascular Diabetology volume 15, Article number: 14 (2016)
Older patients with longstanding type 1 diabetes have high cardiovascular disease (CVD) risk such that statin therapy is recommended independent of prior CVD events. We aimed to determine self-reported CVD prevention guideline adherence in patients with longstanding diabetes.
Research design and methods
309 Canadians with over 50 years of type 1 diabetes completed a medical questionnaire for presence of lifestyle and pharmacological interventions, stratified into primary or secondary CVD prevention subgroups based on absence or presence of self-reported CVD events, respectively. Associations with statin use were analyzed using multivariable logistic regression.
The 309 participants had mean ± SD age 65.7 ± 8.5 years, median diabetes duration 54.0 [IQR 51.0, 59.0] years, and HbA1c of 7.5 ± 1.1 % (58 mmol/mol). 159 (52.7 %) participants reported diet adherence, 296 (95.8 %) smoking avoidance, 217 (70.5 %) physical activity, 218 (71.5 %) renin-angiotensin-system inhibitor use, and 220 (72.1 %) statin use. Physical activity was reported as less common in the secondary prevention subgroup, and current statin use was significantly lower in the primary prevention subgroup (65.5 % vs. 84.8 %, p = 0.0004). In multivariable logistic regression, the odds of statin use was 0.38 [95 % CI 0.15–0.95] in members of the primary compared to the secondary prevention subgroup, adjusting for age, sex, hypertension history, body mass, HbA1c, cholesterol, microvascular complications, acetylsalicylic acid use, and renin-angiotensin system inhibitor use.
Despite good self-reported adherence to general CVD prevention guidelines, against the principles of these guidelines we found that statin use was substantially lower in those without CVD history. Interventions are needed to improve statin use in older type 1 diabetes patients without a history of CVD.
Cardiovascular disease (CVD), which includes myocardial infarction, coronary artery disease (CAD), stroke, and peripheral vascular disease, is often cited as the primary cause of mortality in type 1 diabetes mellitus [1–4]. Though it has been suggested that people with diabetes have a two to fourfold excess risk of developing CVD, in the context of type 1 diabetes the magnitude of this risk approaches tenfold [5–7]. The etiology for amplification of lifetime CVD risk in type 1 diabetes may relate to longer duration of exposure to hyperglycemia [7, 8] in part owing to relatively younger age at diagnosis. Thus, older patients with long duration of type 1 diabetes are a unique group with extremely high lifetime risk of CVD.
More intensive cardiovascular protection measures are recommended for older patients with longstanding diabetes regardless of their CVD history, particularly with regard to pharmacotherapy for lipid control [9, 10]. Clinical guidelines on vascular protection in diabetes recommend the use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (commonly referred to as “statins”) in patients who are over age 40, have long duration of diabetes, or are younger but have existing microvascular complications or additional risk factors [10–12]. The benefits of statin use and lowering LDL cholesterol (LDL-C) in diabetes are strongly supported by studies which demonstrate the effectiveness of statins in reducing risk of vascular events and mortality regardless of prior CVD history [13, 14]. Other general strategies for vascular protection include smoking cessation, dietary modification, regular physical exercise, maintenance of optimal glycemic control, blood pressure, and weight, and the use of renin-angiotensin system (RAS) inhibitors such as angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). The evidence that justifies acetylsalicylic acid use is focused mainly on secondary rather than primary CVD prevention [11, 12]. Ultimately, in the context of long diabetes duration and older age, a key emphasis of guidelines is the use of pharmacotherapy—in particular statin therapy—independent of CVD history.
Despite strong evidence for CVD primary prevention strategies, studies in general practice settings have noted low adherence to these guidelines, possibly due to the nature of preventative rather than therapeutic interventions, expense, concerns about efficacy and side-effects, and limitations in physician-patient relationships [15–18]. Suboptimal statin adherence has been shown in CVD primary prevention (those without history of CVD), with long duration of therapy, and in elderly patients. Under-treatment substantially increases the risk of adverse cardiovascular outcomes and mortality [18–23]. To our knowledge, there are no studies which examine attention to CVD prevention guidelines, and specifically statin use, in patients with longstanding type 1 diabetes.
We aimed to determine whether guideline adherence and self-reported statin use differed between those with and without history of CVD in the baseline phase of the Canadian Study of Longevity in Type 1 Diabetes cohort consisting of patients with 50 years or more of type 1 diabetes at uniformly high risk of CVD. Disparity in the comparison between those with and without CVD history may indicate suboptimal implementation of current clinical practice guidelines and a disregard for longstanding diabetes as a fundamental CVD risk factor.
Research design and methods
This study was conducted as a secondary analysis of the baseline data from the Canadian Study of Longevity in Type 1 Diabetes cohort (JDRF operating grant 17-2013-312). The goal of this analysis was to describe adherence to CVD prevention guidelines—with an emphasis on self-reported statin use—in Canadians living with type 1 diabetes for 50 years or more.
Between April 2013 and December 2014, patients were contacted across Canada through public advertisements, social media, and mailings to health care professionals including primary care physicians, endocrinologists, and pharmacists. Akin to other cohorts, our study included patients with a history of at least 50 years of insulin dependence, as acknowledged through medical documentation or corroboration by a family member [24, 25]. For the Canadian Study of Longevity in Type 1 Diabetes, we anticipated a total cohort sample size of approximately 300 participants based on Canadian 1962 census data and contemporaneous age-specific incidence rates of type 1 diabetes and survival curves [26, 27]. A total of 427 people initially contacted us by toll free number, mail, or e-mail, and 386 eligible participants agreed to participate. By the time of analysis, 309 questionnaires were returned and these participants were included in analysis. Participant flow is summarized in Fig. 1. Participant recruitment and data entry remains ongoing. Participants provided written informed consent, and the study protocol was approved by the ethics committee of the Mount Sinai Hospital (Toronto, ON, Canada).
Data were collected through a 35-page questionnaire in which participants were asked about their diabetes management, family history of CVD, lifestyle and smoking habits, medication use, and history of cardiovascular disease (angina and heart attack), related surgeries (cardiac/leg bypass and angioplasty), hypertension and other medical history including cerebrovascular disease. Furthermore, we obtained from participants’ healthcare providers recent clinical, physical, and laboratory measurements including blood pressure, lipid profile, HbA1c, estimated glomerular filtration rate (eGFR), and fundoscopy examination results.
Lifestyle variables included questions related to diet, smoking, and physical activity: Diet was assessed using seven questions surrounding nutrient and caloric intake, meal patterns, and meal content. Dietary adherence was defined by presence of (1) self-reported consumption of fruits and vegetables and (2) self-reported effort to moderate consumption of dietary carbohydrates and fats. Participants reported presence or absence of current smoking and physical activity, and provided body weight and height from which BMI was calculated. To define pharmacotherapy use, participants were asked to list all current medications, allowing determination of acetylsalicylic acid, statin, ezetimibe, fibrate, and RAS inhibitor use; history of side-effects, drug intolerance, and duration of therapy were not ascertained. As participants were over the age of 40, according to guidelines all participants were eligible for statin use [10–12]. Also according to guidelines, RAS inhibitor use is indicated for participants older than 55 years, with microvascular complications, or with prior CVD history. Subjects meeting these criteria and reporting use of RASi were considered to be adherent .
For descriptive purposes, an “adherence index” was created based on self-reported clinical variables and laboratory results, compared to clinical practice guideline recommendations [10–12]. Participants were assessed for attainment of (1) recommended diet; (2) lack of smoking; (3) reported physical activity; (4) glycemic control [HbA1c ≤7 % (53 mmol/mol)]; (5) blood pressure control (≤130/80 mmHg); (6) LDL-C ≤2.0 mmol/L; (7) maintenance of optimal body weight (BMI <25.0 kg/m2); (8) self-reported use of statin therapy for participants ≥40 years of age (i.e. all study participants); (9) self-reported RAS inhibitor therapy for secondary prevention, age ≥55 years, or age <55 years but with microvascular complications. Adherence was reported as frequency and proportion of participants who attained each recommendation. These recommendations were stratified into domains of lifestyle adherence (recommendations 1–3), clinical target adherence (recommendations 4–7), and pharmacotherapy use (recommendations 8–9). As acetylsalicylic acid use for primary prevention is not unanimously supported by evidence, it was not used in the adherence index.
Nephropathy was defined by the presence on laboratory tests of albumin to creatinine ratio (ACR) ≥2 mg/mmol or an age-adjusted glomerular filtration rate (GFR) <60 ml/min . Presence of retinopathy, and its classification as proliferative or non-proliferative, was obtained by the recent eye specialist examination. Presence of symptomatic diabetic neuropathy was determined through the use of the 15-item, self-administered Michigan Neuropathy Screening Instrument (MNSI) questionnaire. Neuropathy was defined by a score ≥3 .
Primary and secondary prevention subgroups
Participants were stratified into primary and secondary prevention subgroups for comparison. The secondary prevention subgroup consisted of participants who reported any previous diagnosis of coronary artery disease, heart attack or angina, history of cardiac or leg angioplasty, bypass graft surgery, or cerebrovascular disease including stroke. Participants without any of these factors were considered to be in the primary prevention subgroup. As this study was a secondary analysis of cohort data, there were no specific questions about cerebrovascular incidents; history of such events was determined from an open-ended question for participants to report all known medical conditions and history.
SAS version 9.2 (SAS Institute, Cary, NC, USA) was used to perform statistical analysis. Descriptive characteristics were reported as mean ± standard deviation (SD), median and interquartile range (IQR), or as frequency and percent. Statistical comparisons between primary and secondary prevention subgroups were made using the Student’s t test, the Mann–Whitney U test, or the χ2-test, depending on the distribution of the variable. For the adherence index, the χ2-test was used to compare adherence rates between primary and secondary prevention subgroups; Cohen’s kappa coefficient was used to assess agreement among each index. Logistic regression was performed to assess the association of CVD history with self-reported statin use: first univariable models were used to identify other participant characteristics that were significantly associated with statin use. In order to adjust for these potential confounders, these characteristics were then included as independent variables along with CVD history in a final multivariable model, with statin use as the dependent variable. Age, sex, and HbA1c were included a priori, as well as all significant predictors (p < 0.05) in univariable analyses. Multicollinearity among the independent predictor variables was assessed. Odds ratios (OR) are reported along with their 95 % confidence intervals. As a sensitivity analysis, the multivariable model was also run using a stepwise variable selection model. As a second sensitivity analysis, the logistic regression was restricted to the primary prevention subgroup. P-values < 0.05 were considered statistically significant. The sample size was estimated to have a power of 0.81 to detect at least a 15 % difference in proportion of statin use between primary and secondary prevention subgroups, based on the assumptions of approximately 50 % statin use  and 50 % prevalence of CVD in longstanding type 1 diabetes .
Missing data was assumed to be missing at random. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) data was incomplete in that 150(49 %) of values were unreported in the physical exam reports from health care providers. For this reason, self-reported history of hypertension was instead used in the multivariable model, but we performed a sensitivity analysis using SBP. Available-case analysis was used to report patient characteristics, guideline adherence values, and univariable screening, whereas complete-case analysis was used for multivariable regression. To honour variations in threshold values reported by different international organizations that provide clinical practice guidelines, a sensitivity analysis was performed using higher HbA1c of 7.5 % (58 mmol/mol), 8.0 % (64 mmol/mol), and 8.5 % (69 mmol/mol), blood pressure <140/90 mmHg, and BMI <30 kg/m2 targets as cut-offs [12, 30, 31]. Furthermore, as some guidelines recommend special considerations for statin use for patients of extreme age, we performed sensitivity analysis by comparing statin use only among participants who were 75 years or younger .
Patient characteristics are summarized in Table 1 according to the total cohort, primary prevention, and secondary prevention subgroups. The 309 participants had a mean ± SD age of 65.7 ± 8.5 years and median diabetes duration of 54.0 [IQR 51.0, 59.0] years, with 137 (44.5 %) participants being male and 13 (4.2 %) non-Caucasian. Notably, the primary prevention subgroup was significantly younger (64.3 ± 8.5 vs. 68.5 ± 8.3 years, p < 0.001), had shorter diabetes duration (53.0 [50.0, 57.0] vs 57.0 [52.5, 60.5] years, p < 0.001), and contained a smaller proportion of males (82.0 (40.4 %) vs. 55 (52.4 %), p = 0.045). There were no significant differences between primary and secondary prevention subgroups in elements of the family history. Clinical features are shown in the second section of the table. The 309 participants had a BMI of 25.0 [23.0, 28.2], SBP of 128.8 ± 14.9 mmHg, and DBP of 67.4 ± 8.9 mmHg, and 182 (60.3 %) reported history of hypertension. Of these clinical variables, relative to the secondary prevention subgroup, the primary prevention subgroup had a lower proportion of hypertension history (111 (56.1 %) vs. 71 (68.3 %), p = 0.04). For laboratory report values, the whole cohort had HbA1c of 7.5 ± 1.1 % (58 mmol/mol), total cholesterol of 4.1 ± 0.9 mmol/L, and LDL-C of 2.0 ± 0.7 mmol/L. The primary prevention subgroup had lower HbA1c (7.4 ± 1.1 (57 mmol/mol) vs. 7.7 ± 1.1 % (61 mmol/mol), p = 0.04), higher total cholesterol (4.24 ± 0.92 vs. 3.95 ± 0.86, p = 0.02), lower triglycerides (0.77 [0.60, 1.00] vs. 0.83 [0.66, 1.23] mmol/L, p = 0.04), and higher HDL-C (1.79 ± 0.52 vs. 1.58 ± 0.49 mmol/L, p = 0.002). The two subgroups did not differ significantly in LDL-C. Regarding diabetes complications, 193 (71.5 %) had retinopathy, 130 (42.4 %) had neuropathy, and 110 (38.6 %) had nephropathy. The secondary prevention group had a significantly higher proportion of each of these three complications. Medications are presented in the final section of Table 1: a total of 177 (58. %) reported using acetylsalicylic acid, 220 (72.1 %) statin, 23 (7.5 %) ezetimibe, 1 (0.3 %) fibrate, and 218 (71.5 %) RAS inhibitor. Of these, the primary prevention group had markedly lower acetylsalicylic acid, statin, and ezetimibe use than the secondary prevention subgroup.
The distribution of cardiovascular conditions is presented in Fig. 2. Of the entire cohort, 105 (34 %) had cardiovascular conditions (and were included in the secondary prevention subgroup). Within this subgroup, 78 (75.0 %) reported history of heart attack or angina, 52 (50.0 %) had cardiac bypass surgery, 40 (41.2 %) had cardiac angioplasty, 16 (16.5 %) had leg bypass surgery, and 21 (21.4 %) had leg artery angioplasty, and 2 (1.9 %) had cerebrovascular disease. These two individuals also reported history of heart attacks, and one of them had a cardiac bypass surgery.
Adherence to guideline recommendations is summarized in Table 2. The following results are reported for the cohort as a whole: Under the domain of lifestyle recommendations, 52.7 % of participants reported following a recommended diet, 96.8 % did not currently smoke, and 70.5 % reported current physical activity. Based on clinical exam and laboratory reports, 35.0 % had optimal HbA1C ≤7 % (53 mmol/mol), 47.8 % had blood pressure ≤130/80 mmHg, 57.7 % had LDL-C ≤2.0 mmol/L, and 50 % had optimal BMI <25 kg/m2. In terms of pharmacotherapy, 98.1 % of participants were eligible for RAS inhibitors and 72.5 % of these participants were using an ACEi or ARB. Finally, 72.1 % participants reported statin use. Among all participants, 62.5 % of guideline recommendations were met, which was the same between primary and secondary prevention subgroups. Agreement among each component of the adherence index was low (κ < 0.20), except for between statin use and LDL-C (κ = 0.29). The primary and secondary prevention subgroups had similar self-reported adherence to all the above recommendations except for physical activity and statin use. Specifically, compared to the secondary prevention subgroup the primary prevention subgroup had significantly higher proportion of participants who were physically active and lower prevalence of statin use.
In sensitivity analysis, results did not differ when alternate target thresholds were used for HbA1c, blood pressure, and BMI. Furthermore, when statin use was compared only in participants 75 years or younger, the primary prevention subgroup still had significantly lower statin prevalence than the secondary prevention subgroup (117 (65 %) vs 73 (86.9 %), p < 0.001).
Factors associated with statin use
Univariable analyses demonstrated that female sex, hypertension history, higher BMI, lower LDL-C, lower HDL-C, lower total cholesterol, presence of at least one microvascular complication, nephropathy, retinopathy, absence of CVD history, acetylsalicylic acid use, and RAS inhibitor use were associated with the presence of statin use (Table 3). These variables, in addition to age and HbA1c, were used to create a multivariable model as shown in Table 4, which showed that only a higher cholesterol level (adjusted OR = 0.39 [0.25, 0.59] per unit increase in mmol/L, p < 0.001) and absence of CVD history (adjusted OR = 0.38 [0.15, 0.95] for membership in primary prevention subgroup, p = 0.04) were independently associated with lower statin use. Both factors remained significantly associated with statin after a stepwise selection process.
When the logistic regression was restricted to participants in the primary prevention subgroup, sex, age, total cholesterol, BMI, RAAS blockade, and aspirin use were associated with statin use in univariable analysis. When these were included in the multivariable model, only lower total cholesterol was significantly associated statin use.
In the cross-sectional analysis of 309 Canadians with longstanding type 1 diabetes uniformly considered to be at high CVD risk, we observed similar adherence to most general guideline recommendations between the primary and secondary prevention subgroups. However, against prevailing recommendations, the primary prevention subgroup had markedly insufficient statin use—approximately one-third odds relative to the secondary prevention subgroup. Such odds persisted in adjusted analysis to account for potential confounding variables: age, sex, hypertension history, greater BMI, higher HbA1c and total cholesterol, presence of microvascular complications, and acetylsalicylic acid and RAS inhibitor use.
Suboptimal self-reported statin use in the context of the literature
Suboptimal statin use has been commonly reported in a variety of study populations, and is associated with financial, drug-related, health system-related, condition-related, and patient and physician-related factors . Statin use in large clinical trials typically ranges from continuation rates of 70–90 % of trial participants [32–34]. Cross-sectional studies in patients with diabetes in real-world clinical settings have reported much lower rates, generally approximating 50 % prevalence of statin use [35–37]. Most of these studies have been conducted in the context of type 2 diabetes, though some limited data suggests even lower statin use in type 1 diabetes with estimated prevalence below 50 % . Our study addresses this paucity of evidence on statin use in type 1 diabetes by studying individuals with longstanding diabetes who are at high CVD risk and uniformly require statin use for CVD prevention. It is encouraging to note that statin prevalence in our participants (72.1 %) exceeds that in most observational studies, and even approaches the high rates observed in statin clinical trials. Nonetheless, the concern remains that there was a key disparity between primary and secondary prevention subgroups, with about 20 % lower statin use in those without a history of CVD. This implies a significant care gap in the primary prevention of CVD in patients with type 1 diabetes which puts these patients at high risk of a first CVD incident [19, 20]. To estimate the potential clinical implication of this care gap, a simulation study demonstrated that a 25 % increase in statin prevalence in a primary prevention cohort is predicted to avert up to 53 % more CVD-related deaths over 10 years . We therefore hypothesize that increasing statin use among type 1 diabetes patients without a history of CVD to approximate that observed in patients with CVD could represent a substantial strategy to reduce CVD mortality. From a public health perspective, our results suggest that targeting improved statin use in longstanding type 1 diabetes presents an opportunity to decrease the CVD incidence and mortality.
Comparison to literature for other general guideline recommendations
Regarding other CVD prevention recommendations, adherence in our participants was similar to that in other cross-sectional studies in outpatient diabetes settings [35–37]. In fact, it is reassuring that as a whole, our participants had HbA1c, BMI, blood pressure, and lipid measures which were close to or better than guideline recommendations. Remarkably, our cohort had a RAS inhibitor prevalence of 72.5 % amongst eligible participants–similar between primary and secondary prevention subgroups–which approximates that previously found in type 1 diabetes populations . Interestingly, high ACEi and ARB use was uniform between the two subgroups despite greater prevalence of hypertension and nephropathy in the secondary prevention subgroup. This is in contrast to lower statin use in the primary compared to secondary prevention subgroup, even though the two subgroups had similar levels of LDL-C. Perhaps this phenomenon suggests a strong recognition by clinicians and patients of the protective benefits of RAS inhibition, and in contrast, an incorrect but prevailing clinical view that statin use should be limited to those with CVD or dyslipidemia. This data strongly supports the notion that clinicians and patients may not appreciate long diabetes duration as a significant CVD risk factor and are thus reluctant to use statin for primary prevention—a view which has been disproven by the results of many large studies [7–9].
While this study is the first to investigate attention to clinical practice guidelines and self-reported statin use in the context of longstanding type 1 diabetes, and it used mixed methods of data acquisition including self-report, validated questionnaires, and laboratory measures, we recognize some limitations and sources of potential bias. First, our investigation of extreme diabetes duration carries a risk of selection bias—specifically, incidence-prevalence (survival) bias—whereby participants may have had better life-long management of CVD risk compared to those who did not survive to 50 years diabetes duration. However, though the magnitude of adherence and CVD prevalence may be affected by such incidence-prevalence bias, it is unlikely that it would affect the observed association of statin use and the primary and secondary prevention subgroups. Secondly, we acknowledge the risk of recall bias and consequent misclassification error, though we expect these to be small in magnitude given the discernible nature of CVD and current medication use, and we emphasize that such recall bias is non-differential between our analytical subgroups and that the odds ratios presented are unlikely to be influenced by this bias. Third, ascertainment of cerebrovascular disease events may have been incomplete, but the low prevalence of these events is in keeping with known rates from epidemiological study of type 1 diabetes . Fourth, while we believe that our analysis has considered the most fundamental confounders through adjustment, there remains the possibility of unmeasured and residual confounding. For instance, other studies have found retirement and female sex to be associated with lower adherence to statin use and prescription, respectively, [42, 43]; these variables may require further study in our cohort. Fifth, as this study was a secondary analysis, we only determined prevalence of statin use rather than a direct measure of medication adherence such as proportion of days covered by statin prescriptions or reasons—such as medication side-effects—for statin non-use. Finally, our results are specific to those with longstanding type 1 diabetes and may not extend to T2DM or older adult populations without diabetes.
Adherence to cardiovascular protection guidelines—especially statin use—is of fundamental clinical importance because under-treatment in high-risk individuals can worsen cardiovascular disease risk and increase the burden to the healthcare system [17, 23]. This study supports that Canadians with longstanding type 1 diabetes have relatively high self-reported adherence to guidelines and statin prevalence as a whole, but there is inappropriately lower statin use for CVD primary prevention than secondary prevention. In view of this apparent clinical disregard for longstanding diabetes as a fundamental CVD risk factor, our results may serve to encourage improved adherence to evidence-based recommendations for primary prevention of CVD with statins in this population. Future research with this unique cohort should focus on elucidating the causes of suboptimal statin use, and interventions should address statin disparity between primary and secondary CVD prevention in patients with longstanding type 1 diabetes.
Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46(6):760–5.
Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28:2130–5.
Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(suppl 2):S14–21.
Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2013;12:156.
Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81(9):1158–62.
Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035–8.
Zgibor JC, Ruppert K, Orchard TJ, Soedamah-Muthu SS, Fuller J, Chaturvedi N, Roberts MS. Development of a Coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diabetes Res Clin Pract. 2010;88(3):314–21.
Fox CS, Sullivan L, D’Agostino RB Sr, Wilson PW. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham heart study. Diabetes Care. 2004;27:704–8.
Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Smith GD, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
Rabar S, Harker M, O’Flynn N, Wierzbicki AS. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014;349:g4356.
Stone J, Fitchett D, Grover S, Lewanczuk R, Lin P. Canadian diabetes association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: vascular protection in people with diabetes. Can J Diabetes. 2013;37(suppl 1):S61–8.
American Diabetes Association. Cardiovascular disease and risk management. Sec. 8. In standards of medical care in diabetes. Diabetes Care. 2015;38(suppl 1):S49–57.
Perreault S, Dragomir A, Blais L, Lalonde L, White M, Pilon D. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013–24.
Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–16.
Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12:SP11–9.
Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973–85.
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.
Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28(5):574–80.
Slejko JF, Ho M, Anderson HD, Nair KV, Sullivan PW, Campbell JD. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51–7.
Rannanheimo PK, Tiittanen P, Hartikainen J, Helin-Salmivaara A, Huupponen R, Vahtera J, Korhonen MJ. Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in finland. Value Health. 2015;18:896–905.
Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.
Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med. 2008;25(7):850–5.
Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual Risk Reduction Initiative (R3i). Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;24(13):26.
Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, Strauch CM, Monnier VM, Doria A, Aiello LP, King GL. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist Study. Diabetes Care. 2011;34(4):968–74.
Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, Bonner-Weir S, King GL. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: joslin medalist study. Diabetes. 2010;59(11):2846–53.
Bain SC, Gill GV, Dyer PH, Jones AF, Murphy M, Jones KE, Smyth C, Barnett AH. Characteristics of type 1 diabetes of over 50 years duration (the golden years cohort). Diabet Med. 2003;20:808–11.
Prior SL, Jones DA, Gill GV, Bain SC, Stephens JW. Association of the adiponectin rs266729 C > G variant and coronary heart disease in the low risk ‘golden years’ type 1 diabetes cohort. Diabetes Res Clin Pract. 2011;91:e71–4.
McFarlane P, Gilbert R, MacCallum L, Senior P. Canadian diabetes association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: chronic kidney disease in diabetes. Can J Diabetes. 2013;37(suppl 1):S61–8.
Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, Feldman EL, DCCT/EDIC Research Group. Use of the Michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. Diabet Med. 2012;29(7):937–44.
Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:4891.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wrigh JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.
Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H. Scandinavian simvastatin survival study group. randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). 1994. Atheroscler Suppl. 2004;5(3):81–7.
The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA. 1998;279(20):1615–22.
Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The Prevalence of meeting A1C, blood pressure, And LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–9.
Braga M, Casanova A, Teoh H, Dawson KG, Gerstein HC, Fitchett DH, Harris SB, Honos G, McFarlane PA, Steele A, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiol. 2010;26(6):297–302.
Crossman B, Nguyen A, Slavik V, Allan D. Adherence to Canadian diabetes association clinical practice guidelines for patients attending an outpatient diabetes education Centre. Can J Hosp Pharm. 2008;61(3):196–202.
Jones NR, Fischbacher CM, Guthrie B, Leese G, Lindsay RS, McKnight JA, Pearson D, Philip S, Sattar N, Wild SH, Scottish Diabetes Research Network Epidemiology Group. Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006–2008. Diabet Med. 2014;31(6):640–6.
Shroufi A, Powles JW. Evidence-based public health policy and practice: adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J of Epidemiol Comm Health. 2010;64(2):109–13.
Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005;28(2):301–6.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study research group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New Engl J Med. 2005;353(25):2643–53.
Halava H, Westerlund H, Korhonen MJ, Pentti J, Kivimäki M, Kjeldgård L, Alexanderson K, Vahtera J. Influence of retirement on adherence to statins in the insurance medicine all-sweden total population data base. PLoS One. 2015;10(6):e0130901.
Kautzky-Willer A, Stich K, Hintersteiner J, Kautzky A, Kamyar MR, Saukel J, Johnson J, Lemmens-Gruber R. Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2013;24(12):78.
JWB, GB, and BAP performed the primary analysis and wrote the manuscript as primary authors, and BAP is the guarantor for the content of this study. LEL and DE played a principal role in data collection, contributed to discussion, provided statistical support and reviewed the manuscript. EMH, AW, HAK, MB, NP, VB and DZIC contributed to the discussion and reviewed/edited the manuscript. We are extremely grateful to our distinguished study participants, who have greatly inspired our team and spent considerable time participating in this study. The results in this paper were presented in part as a poster abstract at the 75th American Diabetes Association Scientific Sessions in Boston (MA), June 5–9, 2015. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
JWB has received funding from the University of Toronto CREMS Summer Research Program and AW has received a post-doctoral fellowship award from the JDRF Canadian Clinical Trial Network. BAP has received speaker honoraria from Medtronic Inc., Johnson and Johnson, Roche, Glaxo Smith Kline Canada, Novo Nordisk and Sanofi; has received research grant support from Medtronic and Boehringer Ingelheim; and serves as a consultant for Neurometrix. DZIC has received speaker honoraria from Janssen, AstraZeneca, Boehringer Ingelheim, Lilly and Merck and has received research grant support from AstraZeneca, Merck and Boehringer Ingelheim. We are grateful to the Canadian Diabetes Association, JDRF Canada and its Canadian Clinical Trial Network for their support.
Johnny W. Bai and Geneviève Boulet are co-first authors
About this article
- Type 1 diabetes
- Cardiovascular disease
- HMG-CoA reductase inhibitor (3-hydroxy-3-methyl-glutaryl-CoA reductase)